SCHEMBL10679239

SCHEMBL10679239

CCOC(=O)CC(=O)NC(=O)OCC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.61
MGAM O43451 1/20 0.61
SI P14410 1/20 0.61
MGAM2 Q2M2H8 1/20 0.61
MAPT P10636 1/20 0.45
ALDH1A1 P00352 6/20 0.44
TRPA1 O75762 1/20 0.44
TSHR P16473 1/20 0.43
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1413000 0.88 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL15228762 0.82 GAA (0.50) GAAMGAMSIMGAM2MAPT
SCHEMBL11319534 0.82 ALDH1A1 (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL9865139 0.81 GAA (0.46) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL28675119 0.80 GAA (0.46) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL7713280 0.80 GAA (0.55) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL24611006 0.78 GAA (0.56) GAAMGAMSIMGAM2MAPT
Malonic Acid Diethyl Ester SCHEMBL9439825 0.78 GAA (0.88) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL13638352 0.77 GAA (0.42) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL2539602 0.77 GAA (0.42) GAAMGAMSIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340541-A1 METHODS OF PREPARING MODULATORS OF THR-BETA ALIGOS THERAPEUTICS, INC. (US) 2025-11-06 US disclosed
WO-2025137568-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
US-20250206725-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2025-06-26 US disclosed
WO-2021000933-A1 PYRIMIDINONE COMPOUNDS AS CHYMASE INHIBITORS AND APPLICATION THEREOF 南京明德新药研发有限公司 2021-01-07 WO disclosed
US-4772704-A ANTIULCER AGENTS BRISTOL-MYERS COMPANY (US) 1988-09-20 US disclosed
US-4448961-A Substituted anilino pyrimidines ZOECON CORPORATION (US) 1984-05-15 US disclosed
US-4411839-A α-Cyano-β-(trisubstituted phenylhydrazino)-n-ethoxycarbonylacrylamides ZOECON CORPORATION (US) 1983-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206725-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF THRB, THRA, TTR GAA 1578/4885MGAM 3633/4885SI 569/4885
US-20250340541-A1 METHODS OF PREPARING MODULATORS OF THR-BETA THRB, THRA, THRAP3 GAA 929/4885MGAM 2200/4885SI 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.